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ANNEXIN I  is a glucocorticoid-induced mediator with
anti-inflammatory activity in animal models of arthri-
tis.  We  studied  the  effects  of  a  bioactive  annexin  I
peptide,  ac  2–26,  dexamethasone  (DEX),  and  inter-
leukin-1b (IL-1b )  on  phospholipase  A2 (PLA2)  and
cyclooxygenase (COX) activities and prostaglandin E2
(PGE2)  release  in  cultured  human  fibroblast-like
synoviocytes (FLS). Annexin I binding sites on human
osteoarthritic  (OA)  FLS  were  detected  by  ligand
binding flow cytometry. PLA2 activity was measured
using  3H-arachidonic acid release, PGE2 release and
COX  activity  by  ELISA,  and  COX2  content  by  flow
cytometry. Annexin I binding sites were present on
human OA FLS. Annexin I peptide ac 2–26 exerted a
significant concentration-dependent inhibition of FLS
constitutive PLA2 activity, which was reversed by IL-
1b .  In  contrast,  DEX  inhibited  IL-1b -induced  PLA2
activity  but  not  constitutive  activity.  DEX  but  not
annexin  I  peptide  inhibited  IL-1b -induced  PGE2
release.  COX  activity  and  COX2  expression  were
significantly  increased  by  IL-1b .  Annexin  I  peptide
demonstrated  no  inhibition  of  constitutive  or  IL-
1b -induced  COX  activity.  DEX  exerted  a  concentra-
tion-dependent  inhibition  of  IL-1b -induced  but  not
constitutive COX activity. Uncoupling of inhibition of
PLA2 and  COX  by  annexin  I  and  DEX  support  the
hypothesis that COX is rate-limiting for PGE2 synthe-
sis in FLS.  The effect of  annexin I  but not DEX on
constitutive  PLA2 activity  suggests  a  glucocorticoid-
independent role for annexin I in autoregulation of
arachidonic  acid  production.  The  lack  of  effect  of
annexin  I  on  cytokine-induced  PGE2 production
suggests PGE2-independent mechanisms for the anti-
inflammatory effects of annexin I in vivo.
Key  words:  Annexin  I,  Dexamethasone,  Synoviocytes,
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Introduction
Prostaglandins,  such  as  prostaglandin  E2 (PGE2),
mediate the pain and edema associated with arthritis,
leading to the widespread use of non-steroidal anti-
inflammatory  drugs  in  the  treatment  of  arthritis.
Within  the  arthritic  synovial  lesion,  fibroblast-like
synoviocytes (FLS) have been implicated as a primary
source of PGE2.1 In eicosanoid generation, phospholi-
pase A2 (PLA2) and cyclooxygenase (COX, or prosta-
glandin H synthase) have been described as important
regulatory enzymes. The hydrolytic release of arachi-
donic acid from membrane phospholipids is initiated
by  PLA2,  and arachidonic acid is then catalysed by
COX enzymes for the subsequent production of PGE2.
PLA2 exists as a secretory group II isoform (sPLA2)
and  an  arachidonic  acid-selective  cytosolic  form
(cPLA2).2 Two  isoforms  of  COX  have  also  been
identified:  a  constitutive  (COX1)  and  a  mitogen/
growth factor-inducible  (COX2)  form.3 Studies in  a
COX2 gene knock-out animal model demonstrate that
joint inflammation still persists in the absence of this
enzyme.4 At present, the enzymatic events responsi-
ble for the enhanced production of PGE2 in rheuma-
toid arthritis (RA) are not fully  understood. Knowl-
edge pertaining to which enzyme is rate-limiting in
eicosanoid generation in synovium is not fully eluci-
dated. It is known that expression of the cPLA2 and
COX2 are increased by interleukin-1b (IL-1b)5,6 and
that this induction is inhibited by the anti-inflamma-
tory action of dexamethasone (DEX).3,6,7
Annexin I (previously known as lipocortin-1) is a 37
kDa protein which belongs to a family of at least 13
structurally  related  proteins  that  bind  to  anionic
phospholipids in a Ca2+-dependent manner.8 Annexin
I was originally defined as a glucocorticoid-inducible
inhibitor of PLA2 activity.9 The concept that annexin I
may  modulate its anti-inflammatory  actions via  cell
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identification of extracellular annexin I binding sites
on peripheral blood leukocytes.10The involvement of
annexin I in the regulation of joint inflammation has
now  been  demonstrated  in  several  rat  models  of
arthritis,  in  which  a  range  of  biological  actions
extending beyond effects on PLA2 activity has been
suggested.11–13 The possibility that annexin I has anti-
inflammatory activity in human arthritis has not been
previously explored. We sought to further define the
effects of annexin I on PLA2, COX and prostaglandin
production in human FLS, and use the known PLA2
inhibitory properties of annexin I to investigate the
rate-limiting  step  in  synoviocyte  prostaglandin
production.
Materials and methods
Materials
Annexin I ac 2–26 N-terminal derived peptide (acetyl-
AMVSEFLKQAWFIENEEQEYVQTVK)14 was prepared
by use of solid phase step-wise synthesis and obtained
from Prof. Milton Hearn (Monash University, Clayton,
Australia). Purity was more than 99% as determined
by high-performance liquid chromatography. Annexin
I monoclonal antibody 1B was produced from hybrid-
oma  cultures  kindly  donated  by  Dr  J  Browning,
Biogen  Inc.,  Cambridge,  USA,  and  purified  using
saturated  (50%)  ammonium  sulfate  precipitation,
protein A sepharose affinity chromatography. Affi-Gel
10 was purchased from Bio Rad, Australia. RPMI 1640
solution, sodium bicarbonate 7.5% solution, penicillin
(5000 IU/ml)/streptomycin (5000mg/ml), L-glutamine
and  1  ´ trypsin/ethylenediaminetetraacetic  acid
(EDTA)  solution  were  purchased  from  ICN
Biomedicals,  USA.  Human  recombinant  IL-1b
(specific  activity  5.95  ´ 107 U/mg),  DEX,
collagenase  type  II  (specific  activity  >  125  U/mg),
[5,6,8,9,11,12,14,15-H]arachidonic  acid,  bovine
serum  albumin  (BSA)  and  calcium  chloride
were  purchased  from  Sigma,  Australia.
[5,6,8,9,11,12,14,15-3H]arachidonic  acid  (specific
activity  212  Ci/mmol,  1.0  mCi/ml)  was  purchased
from Amersham International plc, Australia. DNase I
from bovine pancreas (specific activity > 2000 U/mg)
and dispase I grade II (specific activity > 0.5 U/mg)
were  purchased  from  Boehringer  Mannheim,  Aus-
tralia.  COX2  monoclonal antibody and positive iso-
type controlmAb, IgG1, were purchased from Trans-
duction Laboratories, USA. Normal human  IgG was
purchased from CSL Pty Ltd, Australia. ControlmAb,
IgG2a,  fluoroisothiocyanate  (FITC)-conjugated  anti-
mouse  IgG  was  purchased  from  Silenus,  Australia.
PGE2 enzyme linked immuno  assay (ELISA) kit was
purchased  from  Neogen  Corporation, USA.  Ultima-
gold scintillation fluid was purchased from Packard
Instrument Company, Australia.
Purification of annexin I protein
Recombinant human annexin I, a generous gift from
Dr Yuko Giga-Hama (Research Centre, Asahi Co. Ltd,
Japan),15 was purified by affinity gel chromatography,
as described by Sakata et al.,16 using purified mono-
clonal  mouse  anti-human  annexin  I  antibody.  To
confirm purification,  samples  of  purified  annexin  I
dissolved in sample buffer were separated on a 12%
gel  using  SDS-polyacrylamide  gel  electrophoresis
techniques.  A  single  37  kDa  protein  band  was
detected by  western  blotting  using  a  specific  anti-
annexin ImAb.
Isolation and culture of FLS
FLS  were obtained from  synovium  of  osteoarthritic
(OA) patients (n = 8) undergoing joint replacement
surgery. All patients satisfied the American College of
Rheumatology criteria for the classification of OA.17,18
FLS  were  isolated  and  cultured  as  described  by
Koch.19,20 In  brief,  the  synovial-lining  tissue  was
dissected and minced into 2–3mm pieces and rotated
in 10ml/2g of enzyme solution containing 2.4mg/ml
dispase (grade II, 5 U/mg), 1mg/ml collagenase (type
II) and 1mg/ml DNase (type I) in Ca2+ and Mg2+ free
Hank’s balanced saline solution. FLS were cultured in
10cm culture plates in RPMI/10% foetal calf serum at
37°C in a 5% CO2 humidified incubator. Cells at 3rd
passage were more than 99% FLS, as demonstrated by
dendritic, spindle morphology, and negative staining
for  the  pan-leukocyte  antigen  CD45  by  flow  cyto-
metry. Cells were used between passages 4 and 9. For
all experiments, FLS were seeded at 1 ´ 105 cells per
well in 24-well culture plates in RPMI/10% FCS and
allowed to adhere overnight, prior to medium being
replaced with RPMI/0.1% BSA for experimental pur-
poses. This study was approved by the institutional
ethics board.
Detection of annexin I binding sites
FLS  were  examined  using  a  method  that  detects
specific saturable annexin I binding sites, as described
by Perretti et al.21 Briefly, surface bound annexin I
was removed by washing with 1mM EDTA/PBS. FLS
were then washed with 0.1% BSA/phosphate buffered
saline (PBS)/1.3mMCaCl2 and resuspended in 20ml
0.2% BSA/RPMI at 4°C and incubated with 0–10mM
of human recombinant annexin I. Annexin I binding
sites  were  detected  by  sequential  incubation  with
60mg/ml  annexin  I  monoclonal  antibody  1B  or
matched isotype controlmAb, IgG2a and FITC-conju-
gated anti-mouse IgG. Fluorescence was analysed on a
MO-FLO flow cytometer (Cytomation, Ft Collins, CO).
Cells were gated according to forward and right angle
scatter,  using  10000  cells  for  each  determination.
Each determination was performed in duplicate, with
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Assessment of PLA2 activity
PLA2 activity  in  FLS  was  determined  according  to
Croxtall et al.22 Briefly, FLS were incubated for 18h
with  1mCi/ml  [3H]arachidonic  acid  in  0.1%  BSA/
RPMI. Cells were treated with 0–100mg/ml annexin I
peptide,  0,  0.1ng/ml  human  recombinant  IL-1b,
10-9–10-7 M DEX for 8h. Triplicate cultures were used
for  each  determination.  Radioactivity  in  the  super-
natant  was  determined  using  a Wallac  1409  liquid
scintillation  counter  (Pharmacia,  Finland),  with
results  expressed  as  tritiated  arachidonic  acid
released, or  as  a  percentage of  the  mean  result  of
unstimulated cells.
Determination of PGE2 levels
PGE2 release  was  determined  by  assaying  treated
supernatants, using  ELISA.  Each  determination was
performed in duplicate, with results expressed as a
percentage of  the  mean  result  of  the  unstimulated
cells. The detection limit for this assay was <0.1ng/ml.
Assessment of COX activity
COX activity was measured according to Wilborn et
al.7 In  brief,  FLS  were  incubated  for  30min  with
10mM  exogenous  arachidonic  acid.  Supernatants
were aspirated and assayed for PGE2 content using
ELISA. Duplicate cultures were used for each determi-
nation. COX activity was expressed as a percentage of
the mean result of the unstimulated cells.
Determination of intracellular COX2
Intracellular expression  of  COX2  in  FLS  was deter-
mined  using  permeabilization  flow  cytometry,  as
described by Morand et al.23 Briefly, cells were fixed
by suspension in 2% paraformaldehyde/PBS, followed
by  permeabilization  using  0.2%  saponin/PBS.  FLS
were  then  sequentially  incubated  with  20mg/ml
COX2mAb  (or  isotype-matchedmAb  control,  IgG1)
and  FITC-conjugated  anti-mouse  IgG.  Permeabiliza-
tion of the cells was reversed with PBS. Labelled FLS
were  analysed  using  flow  cytometry.  10000  cells
were used for each determination. Intracellular COX2
protein was expressed as mean fluorescence intensity
after  subtraction  of  mean  fluorescence  intensity
obtained with negative controlmAb.
Statistical analysis
Results are expressed as the mean ± standard error of
the  mean  (SEM).  Statistical  analysis  was  performed
using  the  Student’s  t-test,  with  values  of  p<0.05
regarded as statistically significant.
Results
We  initially  sought  to  determine  the  presence  of
annexin  I  binding  sites  on  human  FLS.  Annexin  I
binding  sites  as  determined  by  mean  fluorescence
intensity were detected using a concentration range
of  annexin  I (0–10mM).  Results  demonstrated con-
centration-dependent annexin I binding,  with more
than 99% of cells demonstrating annexin I binding at
10mM (Fig. 1, Table 1).
To define the effect of  annexin  I on synoviocyte
PLA2 activity,  FLS  were  treated  with  annexin  I
N-terminal peptide ac 2–26 (0–100mg/ml). Annexin I
peptide induced a significant concentration-depend-
ent inhibition of constitutive PLA2 activity (Fig. 2(a)).
Annexin I effect on synovial fibroblasts
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FIG. 1. Fluorescence histograms of annexin I binding sites on
human  FLS.  FLS  were  incubated  with  rh  annexin  I,  and
annexin I binding detected by flow cytometry after labelling
with  an  anti-annexin ImAb.  Representative  data  obtained
using (a) 0mM and (b)  10mM  annexin I  are depicted. The
x-axis represents mean fluorescence intensity, and the y-axis
the relative cell number. Mean data for 6 experiments are
provided in Table 1.
Table 1. Annexin I binding sites on human FLS
Annexin I
concentration
(mM)
Annexin I
binding
(%)
p value
0  3.7 ± 0.5
1 76.7 ± 4.2 < 0.01
5 97.0 ± 0.4 < 0.01
10 99.5 ± 0.1 < 0.01
Annexin I binding on FLS was detected using a concentration range of
annexin I (0–10mM) and quantitated by flow cytometry. Values are the
percentage  of  cells  expressing  fluorescence  greater  than  that
obtained with a negative controlmAb, and are the mean ± SEM of 6
experiments.  All  concentrations  of  annexin  I  exhibited  significant
binding (p<0.01) compared to cells incubated without annexin I.Inhibition of PLA2 activity by annexin I was reversed
when  cells  were  co-stimulated  with  IL-1b (Fig.
2(b)).
We subsequently  assessed the  effects  of  DEX  on
synoviocyte  PLA2 activity.  DEX  treatment  did  not
significantly inhibit constitutive PLA2 activity over the
concentration  range  10-9–10-7 M.  In  contrast,  DEX
exerted a significant concentration-dependent reduc-
tion of PLA2 activity in IL-1b-stimulated FLS (Fig. 3).
Since annexin I peptide inhibited constitutive PLA2
activity, we next determined whether treatment with
annexin I peptide affected PGE2 release. Constitutive
PGE2 synthesis was detected in FLS. Annexin I peptide
did not significantly reduce constitutive PGE2 synthe-
sis (Fig. 4(a)). A significant increase in PGE2 release
was observed following IL-1b stimulation (p=0.001),
and annexin I peptide did not inhibit IL-1b-stimulated
PGE2 release.  In  contrast,  DEX  had  no  effect  on
constitutive  PGE2 release but  significantly  inhibited
IL-1b-induced  PGE2 release  in  a  concentration-
dependent manner (Fig. 4(b)).
To further address the differential inhibitory actions
of  annexin  I  on  PLA2 activity  and  PGE2 synthesis,
studies  were  designed  to  evaluate  the  effects  of
annexin  I peptide and DEX  on constitutive and IL-
1b-induced synoviocyte COX activity. Since the synthe-
sis of PGE2 from endogenous arachidonic acid results
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FIG.  2.  Effect  of  annexin  I  peptide  on  human  FLS  PLA2
activity.  FLS  were  treated  with  (a)  annexin  I  ac  2–26
(0–100mg/ml),  and/or  (b)  IL-1b (0.1ng/ml)  plus  annexin  I
peptide for 8h. PLA2 activity is expressed as 
3H-AA released.
Values are the mean ±SEM of 8 experiments. *p < 0.05 versus
untreated FLS, p < 0.01 versus untreated FLS.
FIG. 3. Effect of DEX on human FLS PLA2 activity. FLS were
treated with DEX  (10
-9–10
-7 M), and/or  IL-1b (0.1ng/ml) for
8h.  PLA2 activity (
3H-AA  released) is  expressed  as  a  per-
centage of untreated FLS. Values are the mean ± SEM of 8
experiments. *p < 0.01 versus untreated FLS, p < 0.05 versus
IL-1b-treated FLS.
FIG. 4. PGE2 release in human FLS. Human FLS were treated
with  IL-1b (0.1ng/ml),  and/or  (a)  annexin  I  ac  2–26
(100mg/ml), (b) DEX (10
-9–10
-7 M) for 8h. PGE2 release was
quantitated  by  assaying  supernatants  using  ELISA  and
expressed as a percentage relative to untreated FLS. Values
are  the  mean  ±SEM  of  4  experiments.  *p <  0.01  versus
untreated FLS, p < 0.05 versus IL-1b-treated FLS.from the activities of both PLA2 and COX, to estimate
maximal COX activity, PLA2 activity was bypassed by
addition of exogenous arachidonic acid.7 Low levels of
constitutive COX activity were detected in FLS. IL-1b
significantly increased COX activity (p=0.0004) (Fig.
5(a)). Annexin I peptide exerted no significant effect
on constitutive or IL-1b-stimulated COX activity (Fig.
5(a)). DEX exerted no significant effect on constitutive
COX  activity  in  DEX  treated FLS.  In  contrast, DEX
resulted in a concentration-dependent reduction of IL-
1b-induced COX activity (Fig. 5(b)).
The  question  of  whether  modulation  of  COX
activity  reflected  its  intracellular  expression  was
investigated using  permeabilization flow cytometry.
Constitutive expression of intracellular COX2 protein
was  detected  in  FLS,  and  was  increased  by  IL-1b.
Annexin I peptide did not demonstrate any significant
effect on constitutive or IL-1b-stimulated COX2 pro-
tein in FLS (Fig. 6(a)). DEX did not significantly inhibit
constitutive intracellular expression of COX2. How-
ever, DEX exerted a concentration-dependent inhibi-
tion of intracellular COX2 expression in IL-1b-stimu-
lated  FLS  (Fig.  6(b)).  These  results  demonstrate
consistency  between  modulation  of  intracellular
expression of COX2 and its activity.
Discussion
The hypothesis that annexin I is an anti-inflammatory
mediator in arthritis originated from the detection of
annexin I in human rheumatoid synovium.24 Animal
models of arthritis have subsequently  demonstrated
that annexin has important inhibitory effects in vivo.
For  example,  administration  of  annexin  I  peptide
substantially inhibited carrageenan-induced arthritis,
whilst  anti-annexin  I  antibody  exacerbated arthritis
severity and reversed the effect of exogenous DEX in
this model.12 Similarly,  exacerbation of  disease and
increased  synovial  production  of  tumour  necrosis
factor-a and PGE2 were observed in adjuvant arthritic
rats administered anti-annexin I antibody.13 Moreover,
annexin I neutralization reversed the effects of DEX
on disease severity in adjuvant arthritis13 and on rat
synovial  macrophage  nitric  oxide  production.11 In
human  disease,  histological  studies  demonstrate
Annexin I effect on synovial fibroblasts
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FIG. 5. COX activity in human FLS. FLS were treated with IL-
1b (0.1ng/ml), and/or (a) annexin I ac 2–26 (100mg/ml), (b)
DEX  (10
-9–10
-7 M)  for  8h  and  COX  activity  measured  as
described. COX activity is expressed as a percentage relative
to untreated FLS. Values are the mean ± SEM of 4 experi-
ments. *p < 0.01 versus untreated FLS, p < 0.05 versus IL-
1b-treated FLS.
FIG. 6. Intracellular COX2 expression in human FLS. Human
FLS were treated with IL-1b (0.1ng/ml), and/or (a) annexin I
ac 2–26 (100mg/ml), (b) DEX (10
-9–10
-7 M) for 8h. Intracellular
COX2 was detected by permeabilization flow cytometry and
expressed as mean fluorescence intensity (MFI) after sub-
traction  of  MFI  obtained  with  the  negative  controlmAb.
Values are mean ± SEM of 4 experiments. *p < 0.01 versus
untreated FLS, p < 0.01 versus IL-1b-treated FLS.annexin  I  in  the  synovial-lining  layer  of  RA  syno-
vium.24 Annexin  I  expression  in  human  peripheral
blood leukocytes has been described, with maximal
annexin  I content in  neutrophils  and monocytes.23
Moreover, altered annexin I biology is seen in subjects
with RA, who exhibit reduced numbers of annexin I
binding sites on leukocytes compared to controls.25
Impaired glucocorticoid induction of annexin I pro-
duction  has  also  been  noted  in  leukocytes  of  RA
patients,26 and  RA  patients  with  high  titre  anti-
annexin I antibodies exhibit impaired glucocorticoid
responsiveness.27
Treatment  of  undifferentiated  cells  with  gluco-
corticoids increases annexin I transport to the  cell
surface.28The mechanisms whereby annexin I crosses
the membrane are unclear since the protein lacks a
signal  sequence and is  therefore unlikely  to  access
secretory  vesicles  for  release  via  the  conventional
method of exocytosis. The translocation of annexin I
protein  from  intracellular  stores  to  cell  surface
binding  sites  is  believed  to  be  imperative  for  its
function.29,30 Certainly,  extracellular  anti-annexin  I
antibodies significantly reverse the anti-inflammatory
effects of glucocorticoids and simultaneously deplete
intracellular cellular annexin I.11,13,31,32
Evidence that exogenous annexin I modulates its
biological  effects  through  specific  cell  surface
annexin I binding sites originated from the identifica-
tion of these sites on peripheral blood leukocytes.10
Given that annexin I is expressed in RA synovium, it is
conceivable  that  in  FLS,  annexin  I  mediates  its
biological effects via binding to cell surface sites. No
previous study has examined the presence of binding
sites or the biological function of annexin I in human
synovial cells.
The current data establish the presence of annexin
I binding sites on human FLS. The factors influencing
annexin I binding site expression are unclear, and the
absence of molecular identification of the binding site
limits  study  of  its  regulation.  Nonetheless,  having
established  the  presence  of  potentially  biologically
active annexin I binding sites in FLS, we sought to
assess  the  effect  of  annexin  I  on  these  cells.  An
annexin  I  N-terminal  peptide  of  25  amino  acids,
annexin I ac 2–26, has been shown to mimic anti-
inflammatory  actions  of  annexin  I,33,34 including
inhibition  of  arthritis models.11 Perretti et  al.  have
reported that the biological activity of annexin I ac
2–26 is comparable with that of recombinant human
annexin I, albeit at a lower molar potency, and that it
requires binding to cell surface binding sites to exert
its biological effects.34
Previous investigations have evaluated the effects
of glucocorticoids and cytokines on the regulation of
PLA2 and  COX  at  the  levels  of  transcription6,35 or
translation.36 Studies have also compared the level of
activity  of  these  enzymes  in  various  cell  types,
following IL-137 and DEX treatments,7 but studies of
the rate-limiting step at the enzyme activity level in
human  FLS  have not  been undertaken. Our  results
indicate a significant concentration-dependent inhibi-
tion of constitutive but not IL-Ib-induced PLA2 activity
by  annexin  I  ac  2–26.  In A549  cells,  inhibition  of
arachidonic  acid  release  by  annexin  I  peptide  is
believed  to  be  mediated  through  inhibition  of  the
activation of cPLA2 whereby cPLA2 is not phosphory-
lated in the presence of annexin I.38 Details of how
this is accomplished are still uncertain, but binding
site-dependent effects of ac 2–26 are unlikely to relate
to the previously proposed ‘substrate binding’ hypoth-
esis for the effects of annexin I on PLA2. The selective
inhibitory action of DEX on IL-1b-stimulated but not
constitutive cPLA2 transcription and expression has
been  described  in  other  investigations6,35 but  is
confirmed at the enzyme activity level  for  the first
time  in  the  current  study. The  uncoupling  of  the
effects  of  annexin  I  and  glucocorticoids  on  PLA2
supports  the  contention  that  the  constitutive  anti-
inflammatory  effects  of  annexin  I  are  only  in  part
related to mediating the effects of glucocorticoids.
As  previously  demonstrated,  constitutive  PGE2
synthesis  was  detected  in  cultured  FLS.  Cytokine
upregulation of PGE2 synthesis was observed, again
consistent  with  previous  findings.6,36,37 Annexin  I
peptide did not demonstrate any significant inhibitory
effect on constitutive or IL-1-stimulated PGE2 produc-
tion. In rat astrocytes, annexin I peptide reduced but
did  not  abolish  endotoxin-induced  PGE2 release.38
Consistent  with  its  effects  on  PLA2 activity,  DEX
significantly  reduced  IL-1b-stimulated  but  not  con-
stitutive PGE2 release.7,37,38
Annexin  ImAb,  however,  has  been  observed  to
reverse the effects of DEX inhibition on PGE2 release,
and  this  study  also  suggested  that  glucocorticoid
suppression  of  COX  occurs  via  an  annexin
I-independent mechanism.39
Glucocorticoid-induced  suppression  of  COX2
appears  to  be  independent  of  annexin  I  and  is
almost certainly explained by the direct interaction
of the steroid-receptor complex with nuclear factor-
kappa B.40 DEX inhibition  of  cytokine- or mitogen-
induced COX regulation has been previously repor-
ted.6,7,41,42 In  this  study,  regulation  of  intracellular
COX2  expression  was  found  to be  consistent with
regulation of its activity, suggesting that the level of
COX  activity is dependent upon  intracellular  levels
of  COX2.43 The  differential  effects  of  annexin  I
peptide and DEX  on PLA2 activity,  COX,  and PGE2
production support the hypothesis that COX is the
rate-limiting enzyme in IL-1b-induced PGE2 synthesis
in  FLS.  In  contrast,  the  lack  of  effect  of  gluco-
corticoids  on  constitutive  PLA2 and  COX2  activity
suggests  that annexin  I  may  have a  glucocorticoid-
independent role in  constitutive regulation  of  PLA2
activity. Biological  activity of annexin I peptide has
been demonstrated in vivo in rat carrageenan arthri-
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nitric  oxide  and  reactive  oxygen  species.  That
annexin I peptide has previously been demonstrated
to have inhibitory effects on nitric oxide and reac-
tive  oxygen  species  production  in  other  systems
highlights the importance of viewing annexin I not
solely  as an inhibitor of  PLA2 activity.
In summary, three novel findings are reported in
this study. Firstly, the presence of annexin I binding
sites  on  synoviocytes  is  demonstrated.  Secondly,
uncoupling  of  the  effects  of  annexin  I  and  gluco-
corticoids on constitutive and cytokine-induced ara-
chidonic acid generation suggests that annexin I has
glucocorticoid-independent  regulatory  activities  in
inflammation.  Our  results  are  consistent  with  the
conclusion  that  COX2  is  the  rate-limiting  step  in
synoviocyte  PGE2 synthesis,  suggesting  that  PLA2-
directed strategies may not successfully inhibit eico-
sanoid  production  in  arthritis. Thirdly,  the  lack  of
effect of annexin I on PGE2 synthesis, despite clear
effects  on  inflammation  in  vivo,  suggests  the  anti-
inflammatory  effects  of  annexin  I  are  eicosanoid-
independent. For example, annexin I may influence
arachidonic  acid-mediated  intracellular  signal  trans-
duction.  Arachidonic  acid  influences  activation  of
the  Jun-N  terminal  kinase/stress  activated  protein
kinase subgroups of the membrane activated protein
kinase family of signal transduction enzymes, via an
eicosanoid-independent  pathway.44 This  important
pro-inflammatory  signal  pathway  is  also  influenced
by  reactive  oxygen  species,45 also  known  to  be
inhibited by annexin I.46 The possibility that annexin
I  modulates  inflammation  via  eicosanoid-independ-
ent mechanisms remains to be further investigated.
Studies  directed  at  understanding  the  role  of
annexin  I  in  such  pathways  may  have  therapeutic
benefit in  the treatment of  arthritis.
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